NGSX.OB: NeurogesX, Inc. Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, April 11, 2012, 11:04 AM Shares of microcap drug developer NeurogesX (NGSX +30%) soar after saying the FDA has accepted its request for a meeting to discuss ongoing clinical studies of NGX-1998, its product candidate for neuropathic pain. Phase 2 studies were completed at the end of 2011. Comment! [Healthcare, On the Move]
Friday, February 10, 2012, 10:20 AM NeurogesX (NGSX) -20.6% after yesterday's news that an FDA advisory committee did not recommend approval for its Qutenza patch as a treatment for nerve pain related to HIV-associated peripheral neuropathy. Comment! [Healthcare, On the Move]
Thursday, February 9, 2012, 2:36 PM A FDA panel votes 12 to 0 that the Qutenza patch offered by NeurogesX (NGSX) doesn't treat pain in patients afflicted with HIV. Shares are still under a trading halt. Comment! [Healthcare]
Thursday, February 9, 2012, 8:35 AM Trading in both Astex Pharmaceuticals (ASTX) and NeurogesX (NGSX) is halted ahead of a FDA panel meeting on separate drugs for the firms. (FDA agenda: ASTX, NGSX) Comment! [Healthcare]
Tuesday, February 7, 2012, 8:58 AM NeurogesX (NGSX) -21.9% premarket following cautious reports related to FDA approval of its patch for HIV pain. The prescription-strength capsaicin patch didn’t meet its goals in studies for reducing pain caused by neuropathy linked to the virus, an FDA report says. Comment! [Healthcare, On the Move]
Tuesday, November 17, 2009, 9:00 AM Premarket gainers: SMTL +30%. AGO +12%. HLCS +12%. CSE +11%. APWR +11%. DDS +10%. NGSX +9%. SINA +7%. SKS +6%. EJ +6%. CTIC +6%. DPTR +5%. MPEL +4%.
Losers: PSUN -22%. SPWRA -16%. JEC -10%. AOB -9%. BCRX -9%. IRE -9%. CPSL -8%. SII -7%. AIB -7%. NLST -6%. TGP -6%. HOLX -5%. THOR -4%. 1 Comment

NGSX.OB NeurogesX, Inc.

NGSX.OB

NeurogesX, Inc.